Poor patient adherence tends to be a matter of people not taking their medicine as prescribed, due to access barriers. So how can placing an additional burden on patients be the answer? As an industry, we are more than aware … Read More
Breaking News
AARDEX Group Joins Innovative IT4Anxiety Project
Innovative medication adherence tools in a real-world hospital setting to reduce anxiety in users of mental health services. Liege, Belgium – March 3, 2022: Belgium-based AARDEX Group, the global leader in Digital Tools for measuring and managing adherence to medication, today announced they have … Read More
EU Clinical Trials Regulation Creates a Framework for the Future of Research
Recent advances in medical science are providing new hope for people living with unmet needs – but modern medicines are only one side of the coin. Ensuring new treatments move from bench side to bedside as soon as possible is … Read More
Not all Medication Adherence Tools are Created Equal – A Case Study
It may hold the potential to solve one of healthcare’s biggest problems, but not all Medication Adherence Tools are created equal. The key to helping people to take their medicines as prescribed, whether within a clinical trial or as part … Read More
Poor Medication Adherence: A Dangerous yet Modifiable Risk Factor in Psychiatry and Oncology Trials
When it comes to medication adherence in psychiatry and oncology trials, the stakes are high – not taking medicines as prescribed can have life-altering or even life-threatening consequences. As such, we often assume almost perfect adherence. Unfortunately, this could not … Read More
Considerations for Ensuring Optimal Digital Adherence Monitoring
It’s no secret, recruiting clinical trial participants is difficult, time-consuming, and considerably expensive, all while dropout rates are notoriously high across therapeutic areas. Whatever the motive for dropout, the impact is huge. Trials can become underpowered and may not have … Read More
Mitigating the Risk of Trial Failure with Digital Adherence Monitoring
Drug development is inherently risky, with some analysis showing that just 13.8% of products that enter industry-sponsored Phase I trials go on to obtain FDA approval.1 Of course, the exact figure varies across therapy areas and development stages, but it is … Read More
AARDEX and Schreiner MediPharm reinforce their collaboration to Enhance Medication Adherence Management
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence … Read More
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence
AARDEX Group and Pill Connect Ltd Partner to Empower Patient Adherence … Read More
ONdrugDelivery October Issue is now live which includes a contribution of AARDEX Group
AARDEX’s Scientific Lead Bernard Vrijens and Biocorp’s business development director Arnaud Guillet give some details about their companies alliance. They explain how Biocorp’s Injay connected prefilled syringe (PFS) combined with AARDEX’s MEMS Adherence Software provides a mean to tackle the … Read More